- Home
- SAGE vs EU Comparison
SAGE vs EU Comparison
Compare SAGE & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- EU
- Stock Information
- Founded
- SAGE 2010
- EU 2009
- Country
- SAGE United States
- EU United States
- Employees
- SAGE N/A
- EU N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- EU Other Metals and Minerals
- Sector
- SAGE Health Care
- EU Basic Materials
- Exchange
- SAGE Nasdaq
- EU Nasdaq
- Market Cap
- SAGE 571.1M
- EU 538.3M
- IPO Year
- SAGE 2014
- EU N/A
- Fundamental
- Price
- SAGE $9.12
- EU $2.98
- Analyst Decision
- SAGE Hold
- EU Strong Buy
- Analyst Count
- SAGE 18
- EU 1
- Target Price
- SAGE $9.89
- EU $2.75
- AVG Volume (30 Days)
- SAGE 1.8M
- EU 3.3M
- Earning Date
- SAGE 07-30-2025
- EU 08-13-2025
- Dividend Yield
- SAGE N/A
- EU N/A
- EPS Growth
- SAGE N/A
- EU N/A
- EPS
- SAGE N/A
- EU N/A
- Revenue
- SAGE $47,404,000.00
- EU $46,179,000.00
- Revenue This Year
- SAGE $101.71
- EU $27.46
- Revenue Next Year
- SAGE $42.30
- EU $140.12
- P/E Ratio
- SAGE N/A
- EU N/A
- Revenue Growth
- SAGE N/A
- EU N/A
- 52 Week Low
- SAGE $4.62
- EU $1.01
- 52 Week High
- SAGE $13.47
- EU $4.44
- Technical
- Relative Strength Index (RSI)
- SAGE 66.62
- EU 65.93
- Support Level
- SAGE $9.10
- EU $2.52
- Resistance Level
- SAGE $9.36
- EU $2.93
- Average True Range (ATR)
- SAGE 0.10
- EU 0.18
- MACD
- SAGE -0.09
- EU -0.00
- Stochastic Oscillator
- SAGE 29.69
- EU 91.49
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.